A simple test could forecast kidney disease progression

NCT ID NCT07754019

Ongoing Knowledge-focused Sponsor: Bezmialem Vakif University Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This observational study explores whether levels of a protein called soluble CD163 in blood or urine can reflect how active IgA nephropathy is and how it might progress. Researchers will compare these levels among people with IgA nephropathy, those with a similar kidney condition (FSGS), and healthy controls. They will also track kidney function and protein in the urine over time to see if CD163 levels predict outcomes. The goal is to find a noninvasive biomarker that could help monitor the disease without repeated biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If soluble CD163 proves reliable, it could become a simple blood or urine test to gauge kidney inflammation and forecast outcomes, reducing the need for repeated biopsies.
What could go wrong: This is an observational study, not a treatment trial, so it cannot prove cause and effect. The marker may not be specific enough or may not outperform existing tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY

Contacts and locations

Locations

Bezmialem Vakif University Health Application and Research Center

Istanbul, 34093, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.